COX-3 inhibitors in the medical practice: Novel results

A tétel rövid nézete
dc.contributor.advisorSzentmiklósi, József András
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorSalihu, Hauwa Lemu
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék
dc.date.accessioned2022-11-15T08:17:59Z
dc.date.available2022-11-15T08:17:59Z
dc.date.created2021
dc.description.abstractThe COX-3 inhibitors acetaminophen and metamizole are both analgesic and antipyretic drugs with weak anti-inflammatory properties. They primarily work in the CNS through both prostaglandin dependent and independent pathways. These drugs appear to be relatively safer than NSAIDs as they are only weak inhibitors of the peripheral cyclooxygenases. Acetaminophen is associated with liver toxicity, but this only occurs in doses higher than the daily recommended dose, and in patients with a weakened liver function. Metamizole is known to be associated with agranulocytosis, but it was proven that the estimated incidences were greatly exaggerated and that metamizole is relatively safe compared to other well-known analgesics.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent41
dc.identifier.urihttps://hdl.handle.net/2437/339816
dc.language.isoen
dc.subjectCOX-3
dc.subjectMetamizole
dc.subjectAcetaminophen
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titleCOX-3 inhibitors in the medical practice: Novel results
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)